Early Access — free while we kick the tires
EdgarHawk

Phanstiel S. Louise

Director

Director
2 filings analyzed · 2 companies · Latest 2026-02-27

Companies

Company Buys Sells Direction
MYRIAD GENETICS INC MYGN 3 0 Net buying
Butterfly Network, Inc. BFLY 1 0 Net buying

Activity

February 2026
2026-02-27 MYRIAD GENETICS INC MYGN
medium
Buy
104,507 shares
$494,722
Significance 6/10

Director Phanstiel S. Louise bought 104,507 shares over 3 days at average $4.73; holdings rose 58.9% to 281,951 shares

Phanstiel S. Louise executed 3 separate purchases totaling 104,507 shares for $494,722.42 between 2026-02-25 and 2026-02-27 at an average blended price of $4.73, increasing her holdings by 58.9% to 281,951 shares. The transaction occurred in a context of significant stock price weakness: MYGN trades at $4.61 currently, down 66.6% from its 52-week high of $13.78 and down 39.6% over the past 90 days. The company reported a net loss of $27,400,000 for its latest quarter and is unprofitable on a full-year basis, with flat annual revenue growth of -1.6%. The director's prior open-market purchase across all tickers returned +60.6% over 30 days on average, though this cross-ticker track record does not constitute predictive evidence specific to MYGN.

December 2025
medium
Buy
185,261 shares
$571,160
Significance 5/10

Director Phanstiel buys 185,261 shares at $3.08; first position in unprofitable BFLY mid-recovery phase

Phanstiel S. Louise, a director, established a new position of 185,261 shares at $3.08, representing a $571,159.66 investment. This is her first shareholding in Butterfly Network, which reported net income of $-34.0M against revenue of $21.5M in the latest quarter and remains unprofitable on a full-year basis. The timing coincides with a significant 30-day rally of +60.9% and 90-day gain of +67.7%, though the stock remains -34.2% below its 52-week high of $4.82. The company shows underlying revenue growth of +24.5% year-over-year, indicating operational momentum despite current losses. The director's acquisition during a recovery phase in an unprofitable company warrants investor attention to whether this reflects confidence in a turnaround trajectory or signals the board's assessment of valuation.

Related insiders

Create a free account

Build watchlists, get email alerts on the tickers you follow, and read the full AI analysis on every insider filing.

Sign up — free during early access